24 results about "Affinity Reagent" patented technology

Disclosed herein are chromatographic materials comprising crosslinked streptavidin molecules. The crosslinked streptavidin chromatographic materials may be used to prepare affinity chromatographic materials using biotinylated affinity agents, such as a biotinylated antibody, biotinylated antigen-binding fragment, or biotinylated oligonucleotide. Due to the crosslinked nature of the streptavidin molecules, the materials provided herein have reduced to no streptavidin leachate, resulting in improved performance.

Single-cell multi-omics by co-encapsulating a single cell with two beads, the first an RNA barcoding bead having barcoded mRNA capture primer oligonucleotides attached on the bead surface; and the second a DNA barcoding bead having two types of oligonucleotides releasably attached to the surface: (1) barcoded adapter oligonucleotides that are complementary to oligonucleotides bound to the transposase that are eventually incorporated into gDNA fragments and (2) polyadenylated barcoded oligonucleotides containing the same barcode sequence as the adapters. In addition, integrated analysis of RNA and protein, including intracellular protein, from individual cells using similar co-encapsulation of a single cell, an RNA barcoding bead, and with / without a specific or non-specific protein binding bead in a microwell, to avoid protein fixation by first lysing the cell to liberate intracellular contents, and then capturing protein either on a solid surface or in solution with barcoded affinity reagents.

The invention discloses a method for synthesizing chiral morpholine from propargyl alcohol ester. Chiral morpholine is an important drug molecular skeleton and is widely applied to the aspects of analgesia, anesthesia, tumor resistance, heart treatment and the like as a drug active ingredient, but an efficient synthesis method is lacked. According to the method disclosed by the invention, under the regulation and control of arylboronic acid and a specific chiral ligand, propargyl alcohol ester and an affinity reagent react to obtain optically pure (87-97% ee) morpholine. The method has the characteristics that the catalyst and the ligand are wide in source, and the substrate is cheap and easy to obtain; the chiral morpholine has excellent enantioselectivity and good functional group compatibility, can be suitable for structural modification of bioactive molecules and intermediates, and is a simple and efficient asymmetric catalysis strategy for synthesizing chiral morpholine.

Provided herein are techniques relating to the identification of binding sites of DNA binding proteins, and in particular, but not exclusively, to methods, systems and kits for simultaneous mapping of binding sites of multiple proteins in the same cell using affinity reagent specific barcodes.

Provided herein are nanobodies, polypeptides comprising the same, and uses thereof. The nanobody's variable region includes 3 complementarity determining regions (CDRs) and framework regions (FRs), wherein the CDRs are as follows: CDR1: Ser-Gly-Xaa11-Xaa12-Phe-Xaa13-Xaa14-Asn-Xaa15 (Formula I); CDR2: Xaa21-Thr-Xaa22-Xaa23-Gly-Xaa24-Thr (Formula II); CDR3: His-Xaa31-Asp-Glu-Xaa32-Arg-Xaa33-Ser-Xaa34-Trp-Thr-Thr-Ser-Asn-Xaa35 (Formula III). The nanobodies and their polypeptides exhibit high affinity and activity, specifically recognizing and binding AAV. Affinity agents prepared therefrom have strong AAV adsorption capacity, suitable for AAV affinity chromatography to facilitate its industrial application. They are also applicable to AAV detection, enabling simultaneous detection of empty capsids and viral particles.

This invention belongs to the field of rapid detection technology, specifically relating to a rapid, real-time detection method for influenza A based on electrochemical biosensors. This invention provides an aptamer that specifically recognizes the influenza A virus, and uses a pairing affinity reagent to enrich the aptamer onto magnetic beads to prepare a probe that specifically recognizes the influenza A virus. Then, using this probe, MB solution, and screen-printed electrodes, an electrochemical biosensor that specifically recognizes the influenza A virus is fabricated. Qualitative or quantitative detection of influenza A virus using the electrochemical biosensor of this invention eliminates the need for complex pretreatment and viral nucleic acid amplification, greatly simplifying the operation. The results are stable and reliable, making it suitable for real-time detection applications.

A method of identifying extant proteins, including (a) inputting to a computer processor: (i) a plurality of empirical binding profiles, individual empirical binding profiles including empirical binding outcomes for binding of an extant protein to a plurality of different affinity reagents, (ii) a plurality of candidate outcome profiles, individual candidate outcome profiles including binding outcomes for binding of a candidate protein to the plurality of different affinity reagents, and (iii) a plurality of pseudo outcome profiles, individual pseudo outcome profiles including a rearrangement of a candidate outcome profile; (b) performing a process in the computer processor to identify extant proteins based on the empirical binding profiles of the extant proteins and the plurality of candidate outcome profiles; and (c) performing a process in the computer processor to determine a false discovery statistic for the extant proteins based on the plurality of pseudo outcome profiles.

The present disclosure provides a method of identifying a polypeptide. The method can include steps of (a) attaching a polypeptide to a particle or solid support, thereby producing an immobilized polypeptide having a plurality of amino acids linked to the particle or solid support; (b) fragmenting the immobilized polypeptide, whereby the particle is attached to a set of fragments of the polypeptide; (c) performing a binding assay including contacting the set of fragments with a plurality of affinity reagents and detecting binding of affinity reagents of the plurality of affinity reagents to the set of fragments; and (d) identifying the polypeptide from results of the binding assay

Novel bispecific and multispecific antibodies having differentially modified light chains, that allows for isolation of the bispecific or multispecific antibodies based on a differential affinity towards an affinity reagent.

A marker for analysing a biological sample includes an affinity reagent comprising an affinity reagent oligonucleotide with a barcode sequence, a label comprising a label oligonucleotide with a complementary barcode sequence at least partially complementary to the barcode sequence of the affinity reagent oligonucleotide, and at least one blocking oligonucleotide with a blocking sequence that is partially complementary to the barcode sequence of the affinity reagent oligonucleotide or to the complementary barcode sequence of the label oligonucleotide.

The invention relates to a device for separating different cell types, comprising a rotatable chamber (10) with a first side (21) which has at least one first affinity reagent (31) for at least one first cell type, and a second side (22) opposite the first side (21) which has at least one second affinity reagent (32) for at least one second cell type. In a method for separating different cell types using the device, a suspension having at least one first cell type and at least one second cell type is introduced into the chamber (10), and the chamber is rotated so that at least once the first side (21) and at least once the second side (22) is arranged at the bottom.

In a first aspect, a marker (100, 300, 400) for analyzing a biological sample is provided. The marker (100, 300, 400) includes an affinity reagent (108, 406, 408) configured to specifically bind to a target analyte (110, 500) of the biological sample. The marker (100, 300, 400) further comprises a tagging moiety (106, 200, 414, 416) and a nucleic acid construct (102, 302) configured to associate the tagging moiety (106, 200, 414, 416) with the affinity reagent (108, 406, 408). The nucleic acid construct (102, 302) comprises a triplex structure (104). In another aspect, a method for analyzing the biological sample is provided.

Methods and systems are provided for accurate and efficient identification and quantification of proteins. In an aspect, disclosed herein is a method for iteratively identifying candidate proteins within a sample of unknown proteins, the method comprising receiving information of binding measurements of each of a plurality of affinity reagent probes to the unknown proteins, each affinity reagent probe configured to selectively bind to one or more candidate proteins; comparing at least a portion of the information of binding measurements against a database comprising a plurality of protein sequences, each protein sequence corresponding to a candidate protein; and iteratively generating a probability that each of one or more candidate proteins is present in the sample based on the comparison of the information of binding measurements of the candidate proteins against the database comprising the plurality of protein sequences.

In a first aspect, a marker (100, 200) for analyzing a biological sample is provided. The marker (100, 200) comprises an affinity reagent (104) comprising an affinity reagent oligonucleotide (108) having a barcode sequence (110). The marker (100, 200) further comprises a marker (112) comprising a marker oligonucleotide (114) having a complementary barcode sequence (116) that is at least partially complementary to the barcode sequence (110) of the affinity reagent oligonucleotide (108). The marker (100, 200) further comprises at least one blocking oligonucleotide (102, 202) having a blocking sequence (118, 204) that is only partially complementary to the barcode sequence (110) of the affinity reagent oligonucleotide (108) or to the complementary barcode sequence (116) of the marker oligonucleotide (114).

An affinity reagent, having: (a) a retaining component such as a structured nucleic acid particle; and (b) one or both of (i) one or more label components attached to the retaining component, and (ii) one or more binding components attached to the retaining component.

Methods and systems are provided herein for selecting an affinity reagent which binds a desired peptide epitope in a plurality of sequence contexts. The method relies on obtaining a peptide library, each peptide having the sequence αXβ, wherein X is the desired peptide epitope, wherein each of α and β comprise an amino acid, using the peptide library to select an affinity reagent.

The invention relates to an apparatus for separating different cell types, comprising a rotatable chamber (10) having a first side (21) which comprises at least one first affinity reagent (31) for at least one first cell type and a second side (22) which is opposite the first side (21) and comprises at least one second affinity reagent (32) for at least one second cell type. A process for separating different cell types using the apparatus comprises introducing a suspension comprising at least one first cell type and at least one second cell type into the chamber (10) and rotating the chamber so that the first side (21) and the second side (22) are each situated at the bottom at least once.

The invention provides an isolated peptide comprising a lysine 2-hydroxyisobutyrylation site, a lysine 2-hydroxyisobutyrylation specific affinity reagent that specifically binds to the peptide, and a method for detecting protein lysine 2-hydroxyisobutyrylation in a sample using the reagent.

Disclosed herein are compositions comprising capture agents that binds specifically to a first epitope of an analyte and a detection agent that specifically binds to a second epitope of the analyte, the detection agent comprising a unique nucleic acid barcode for identifying the presence of the analyte in a sample. Methods for using the compositions and making the detection agents are also disclosed.

A connector is provided for analysing biological samples including at least one first affinity reagent configured to bind directly or indirectly to a target molecule, and a backbone connected to the first affinity reagent and having at least one first affinity interactor, wherein the first affinity interactor is configured to specifically bind to a second affinity interactor having a label in order to bind the label to the backbone, and wherein the backbone has a cleavage site for irreversibly separating the first affinity reagent and the first affinity interactor. In a further aspect, a marker and a method for analysing biological samples are provided.

Molecules that bind proteins of interest — known as "binders" or "affinity reagents" are useful for basic research, diagnostic, and therapeutic purposes. Provided herein are methods and compositions for generating such molecules in a high-throughput manner without burdensome optimization of selection conditions, as well as uses thereof.

This invention provides methods and systems for accurate and efficient protein identification and quantification. [Solution] A method for repeatedly identifying candidate proteins in a sample of an unknown protein is disclosed, comprising the steps of: receiving information on binding measurements for each of a plurality of affinity reagent probes for the unknown protein, wherein each affinity reagent probe is configured to selectively bind to one or more candidate proteins; comparing at least a portion of the binding measurement information with a database containing a plurality of protein sequences, wherein each protein sequence corresponds to one candidate protein; and repeatedly generating the probability that each of the one or more candidate proteins is present in the sample, based on the comparison of the binding measurement information of the candidate proteins with a database containing a plurality of protein sequences.

The disclosure provides in certain aspects engineered lipid bilayer particles, including targeted extracellular vesicles, enveloped viral vectors (e.g., lentiviral vectors), and virus-like particles, having increased capacity for performing targeted delivery to specific cells of interest by inclusion of an effective new "affinity reagent" (herein which may also be referred to as a "targeting chimeric polypeptide" or equivalently "chimeric targeting polypeptide") in the lipid bilayer membrane of such particles.